RT Journal Article
SR Electronic
T1 COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined by Machine Learning Approaches
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.29.20164699
DO 10.1101/2020.07.29.20164699
A1 Huang, Jia
A1 Zhai, Song
A1 Ye, Fangfan
A1 Wang, Song
A1 Zeng, Manfei
A1 Way, George
A1 Madahar, Vipul
A1 Zhu, Tengfei
A1 Qiu, Liping
A1 Xu, Zehui
A1 Ye, Manhua
A1 Liu, Lei
A1 Cui, Xinping
A1 Liao, Jiayu
YR 2020
UL http://medrxiv.org/content/early/2020/08/01/2020.07.29.20164699.abstract
AB Various medical treatments for COVID-19 are attempted. After patients are discharged, SARS-CoV-2 recurring cases are reported and the recurrence could profoundly impact patient healthcare and social economics. To date, no data on the effects of medical treatments on recurrence has been published. We analyzed the treatment data of combinations of ten different drugs for the recurring cases in a single medical center, Shenzhen, China. A total of 417 patients were considered and 414 of them were included in this study (3 deaths) with mild-to-critical COVID-19. Patients were treated by 10 different drug combinations and followed up for recurrence for 28 days quarantine after being discharged from the medical center between February and May, 2020. We applied the Synthetic Minority Oversampling Technique (SMOTE) to overcome the rare recurring events in certain age groups and performed Virtual Twins (VT) analysis facilitated by random forest regression for medical treatment-recurrence classification. Among those drug combinations, Methylprednisolone/Interferon/Lopinavir/Ritonavir/Arbidol led to the lowest recurring rate (0.133) as compared to the average recurring rate (0.203). For the younger group (age 20-27) or the older group (age 60-70), the optimal drug combinations are different, but the above combination is still the second best. For obese patients, the combination of Ribavirin/Interferon/Lopinavir/Ritonavir/Arbidol led to the lowest recurring rate for age group of 20-50, whereas the combination of Interferon/Lopinavir/Ritonavir/Arbidol led to lowest recurring rate for age group of 50-70. The insights into combinatorial therapy we provided here shed lights on the use of a combination of (biological and chemical) anti-virus therapy and/or anti-cytokine storm as a potentially effective therapeutic treatment for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUniversity of California, Riverside. Grant Number: AES‐CE RSAP A01869 for Cui; UCR Academic Award to Jiayu Liao; and National Natural Science Foundation of China (No. 81501651 to Jia HuangAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All the treatment plans were approved by the IRB committee of The Second Affiliated Hospital of Southern University of Science and Technology.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data are available upon request, except patient identity information.